BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 2, 2026
See today's BioWorld MedTech
Home
» FDA establishes new interoperable insulin pump device class – with Tandem up first
To read the full story,
subscribe
or
sign in
.
FDA establishes new interoperable insulin pump device class – with Tandem up first
Feb. 19, 2019
By
Stacy Lawrence
Tandem Diabetes Care Inc. saw its shares climb almost 20 percent this week, just as it became the first company to have a product classified in a new FDA category: Alternate Controller Enabled Infusion Pumps (ACE pumps).
Medical technology